A Phase 3 interventional study of Telitacicept and Placebo in Primary Sjogren's Disease, sponsored by Vor Biopharma. Recruiting at 49 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Vor Biopharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.
Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 16th largest by planned enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 15 of the 27 other live ones, and was the 106th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
National Institute of Dental and Craniofacial Research (NIDCR) · Sites in United States
Ages 18–75
Center For Sight · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 36 · Phase 3 14 · Phase 4 3
First in 1984; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 57 across the 76 interventional studies, 220 across the 35 observational. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 111 have an industry lead sponsor. The 10 most frequent:
Vor Biopharma is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Vor Biopharma has 1 study filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Sjogren's Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT07277257Center For SightEvaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome | 2026-12-31 |
| NCT03276923Duke UniversityMaternal Autoimmune Disease Research Alliance (MADRA) Registry | 2027-01-01 |
| NCT07732582Tufts UniversitySjogren's Mini-Pill Oral and Gut Microbiome Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Sjogren's Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Telitacicept (RC18) is a recombinant fusion protein designed to target B-cell-mediated immune pathways. It consists of the extracellular domain of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) linked to the Fc portion of human immunoglobulin G1 (IgG1).
Telitacicept binds with high affinity to the cytokines B-lymphocyte stimulator (BLyS, also known as BAFF) and A Proliferation-Inducing Ligand (APRIL). By binding these soluble factors, telitacicept prevents their interaction with cell-surface receptors on B cells, including TACI, B-cell maturation antigen (BCMA), and BAFF receptor (BAFF-R).
This inhibition reduces BLyS/APRIL signaling, leading to decreased B-cell survival, reduced differentiation of B cells into immunoglobulin-producing plasma cells, and lowering of autoantibody production, increased BLyS and APRIL levels, B-cell hyperactivity, and autoantibody production are associated with multiple autoimmune diseases.
Modulation of the BLyS/APRIL pathway is intended to reduce pathogenic B-cell activity and downstream immune effects that contribute to disease manifestations in Sjogren's disease and other B-cell-mediated autoimmune conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria are defined in the protocol
Exclusion Criteria:
Additional exclusion criteria are defined in the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telitacicept
Biological: Telitacicept
Placebo
Drug: Placebo
Subcutaneous injection
Also known as: RC18, RC18-L
Subcutaneous injection
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.
Change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.
Time frame: Week 48
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the treatment of adult participants with pSD.
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the treatment of adult participants with pSD.
Time frame: Week 48
To evaluate the efficacy of telitacicept versus placebo in improving glandular function during the trial.
Change from baseline in the stimulated whole salivary flow at Week 48.
Time frame: Week 48
To evaluate the effect of telitacicept versus placebo in improving patient-reported outcomes (i.e., how participants feel and function) during the trial.
Change from baseline in the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score at Week 48
Time frame: Week 48
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the physician's global assessment of disease activity (Physician GDA) score at Week 48
Change from baseline in the physician's global assessment of disease activity (Physician GDA) score at Week 48
Time frame: Week 48
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score at Week 48
Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score at Week 48
Time frame: Week 48
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the participant's global assessment of disease activity (Patient GDA) at Week 48.
Change from baseline in the participant's global assessment of disease activity (Patient GDA) at Week 48.
Time frame: Week 48
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telitacicept
Vor Biopharma